Browsing Tag
CTIM-76
2 posts
Could Context Therapeutics’ CLDN6 T cell engager strategy gain traction after ovarian cancer results?
Find out how Context Therapeutics’ CTIM-76 ovarian cancer data could shape its CLDN6 T cell engager strategy and investor outlook.
Why Context Therapeutics (NASDAQ: CNTX) jumped on CTIM-76 fast track status and what comes next
Context Therapeutics stock rose after CTIM-76 won FDA fast track status. Read what it means for CNTX, ovarian cancer strategy, and the June 2026 data catalyst.